News >

Rizvi Highlights Impact of Immunotherapy and Next Steps NSCLC

Brandon Scalea
Published: Tuesday, Mar 12, 2019

Naiyer A. Rizvi, MD

Naiyer A. Rizvi, MD

Immunotherapy has dramatically improved the outlook for select patients with metastatic non–small cell lung cancer (NSCLC), but its reach could extend even further when combined with other approaches, said Naiyer A. Rizvi, MD.

Additionally, in December 2018, the FDA approved the frontline combination of atezolizumab (Tecentriq), bevacizumab (Avastin), paclitaxel, and carboplatin for the first-line treatment of patients with metastatic nonsquamous NSCLC.

Beyond the metastatic setting, checkpoint inhibition is also starting to make headway in patients with stage III disease. For example, data from the PACIFIC trial showed a significant survival advantage with the addition of durvalumab (Imfinzi) to standard concurrent chemoradiation therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication